Drug Trial Radar · NCT07456059
A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Mar 10, 2026
Primary completion
Jun 1, 2026
Study completion Jun 1, 2026
Sponsor
- Lead sponsor
- Edgewise Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after single and multiple doses in Japanese and Caucasian adults. The safety of EDG-7500 in these adult participants will also be evaluated in this study.
Conditions
- Healthy Adult Participants
Interventions
EDG-7500Drug
Solid oral formulation of EDG-7500
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC0-lastTime frame: Day 1 to Day 13
- AUC0-infTime frame: Day 1 to Day 13
- AUCtauTime frame: Day 1 to Day 13
- CmaxTime frame: Day 1 to Day 13
- Cmax,ssTime frame: Day 1 to Day 13
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.